Re: Farmas USA
Noticia de ZLCS
Canaccord Genuity reiterates a 'Buy' on Zalicus (NASDAQ: ZLCS) price target of $3.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on Synavive’s potential in rheumatoid arthritis (RA) and emerging pain platform. Synavive is ZLCS’ Ph2 drug for RA, with major market potential in various conditions treated with low dose chronic steroids. ZLCS also has a promising ion channel modulator platform for chronic pain, including Ph2a-ready Z160, a novel Ca2+ channel blocker
Compradas unas poquitas mas.